PARIS--(BUSINESS WIRE)--Regulatory News:
EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today the decision from the Center for New Health Technology (NECA) to grant the EOS imaging platform the Innovative Technology status, recognizing EOS as a unique modality worthy of a new reimbursement code with higher coverage than conventional X-rays.
The New Health Technology Assessment Committee was established in July of 2000 under the Ministry of Health and Welfare to look at the safety, effectiveness and cost effectiveness of relevant technologies as well as the social, ethical and legal effects. The Committee uses a systematic literature review to search, analyze and contemplate existing studies comprehensively and without bias as the basis for evaluating the applications. EOS was granted the Innovative Technology status on the basis of the combination of innovations in dose reduction, simultaneous biplanar scanning and 3D reconstruction capacity.
Now that EOS imaging has received the New Health Technology Notice, an EOS exam will be registered in the health insurance benefits coverage list as a specific modality. During the coming years, EOS exam reimbursement levels will be determined. In the meantime, hospitals may determine for themselves the amount they will charge for each EOS exam, allowing immediately utilizing EOS in better financial conditions.
EOS imaging received the Korean Food and Drug Administration (KFDA) clearance in 2014. The approval from the NHTA is an important step towards EOS imaging’s ability to develop in the Korean medical imaging market. Korea is the third market in Asia for imaging equipment and is making strong investments to become a world leader in the medical device industry with a particular emphasis on medical imaging equipment and processing software.
Marie Meynadier, CEO of EOS imaging said, “The EOS platform is an exciting new modality in the orthopedic imaging market, and enhanced reimbursement can obviously contribute to the pace at which it is becoming a standard of care. We are pleased that the Korean NECA committee recognized how innovative our technology is, the value our solution offers patients and the role that appropriate reimbursement will play in the availability of our solutions to the people of Korea.”
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: 2015 Full-year results and 2016 First-quarter sales on April 28, 2016
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2015 revenues of €21.8 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.